Appointed
Andrew Regan
Chief Executive Officer
CDT ·
CDT Equity Inc.
On April 15, 2025, the Company appointed Andrew Regan as Chief Executive Officer, effective immediately.
Ready 8-Ks
41
Latest filing
May 28, 2026, 4:30 PM ET
Top materiality
0.85
Event mix
other_material ×21 · other ×6 · regulatory ×5
Sentiment
5 pos · 11 neg · 25 neu
Executive change
recent →
Recent 8-K filings for CDT
Highest-materiality recent filing
Nasdaq notifies Conduit of delisting due to low price; shareholders approve reverse stock split
- Closing bid price ≤ $0.10 for 10 consecutive days; delisting set for Dec 27 unless hearing requested.
- Company intends to request a hearing before Nasdaq Hearings Panel; delisting stayed pending decision.
-
Received Nasdaq deficiency notice on May 21, 2026 for failing to timely file Q1 2026 Form 10-Q under Listing Rule 5250(c)(1).
-
CDT Equity Inc. announces 1-for-25 reverse stock split effective March 26, 2026
Reverse stock split at 1:25 ratio; effective March 26, 2026 at 5:00 pm ET.
-
Redomestication from Delaware to Cayman Islands approved (Proposal 6): ~2.22M for, 72K against, 21.9K abstain.
-
CDT Equity lowers ELOC floor to $0.60 and issues $555K convertible note
Amendment cuts ELOC floor price to $0.60; max shares issuable ~41.7M, subject to stockholder approval.
-
CDT Equity acquires 20% of Sarborg for stock, warrants, deferred $8M cash
Acquired 1,020 Sarborg shares (~20% stake) in exchange for 598,006 shares + pre-funded warrants for 109,978,918 shares at $0.0001 exercise price.
-
CDT Equity enters $25M equity line of credit with Ascent Partners; issues 204,031 commitment shares
CDT Equity entered a directed stock purchase agreement for up to $25M of common stock with institutional investor Ascent Partners.
-
CDT sells CPL subsidiary to CEO affiliate Corvus for $7M to offload Strand litigation liability
CDT sells CPL to Corvus Capital (wholly-owned by CEO Andrew Regan) for $7M in common stock or pre-funded warrants.
-
CDT Equity restates Q1 2025 financials; $0.4M milestone misclassified as R&D
On Aug 8, 2025, CDT Equity determined its unaudited Q1 2025 financials should no longer be relied upon.
-
Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.
-
Conduit Pharma stockholders approve reverse stock split up to 1-for-250 at special meeting
Proposal passed with 5,065,868 votes for, 496,473 against, 1,438 abstentions.
-
Marcum LLP resigned as independent auditor on April 24, 2025; CBIZ CPAs P.C. appointed on April 25, 2025.
-
Conduit Pharma appoints founder Andrew Regan as CEO; Tapolczay transitions to licensing role
David Tapolczay resigned as CEO and board member effective April 12, 2025; to serve as Head of Licensing & Strategy at £240K salary.
-
Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares
Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.
-
Conduit Pharmaceuticals regains full Nasdaq compliance after $8.3M raise and debt conversion
Submitted pro-forma financials showing stockholder's equity of $2.8M vs $2.5M minimum required.
-
Conduit Pharmaceuticals provides Nasdaq compliance update; equity above $2.5M threshold
Submitted pro-forma financials showing Stockholder's Equity of $2.8M as of March 31, 2025, above Nasdaq's $2.5M minimum.
-
Conduit Pharmaceuticals receives Nasdaq extension, plans transfer to Capital Market
Nasdaq Hearing Panel granted extension to March 31, 2025 to regain MVPHS and MVLS compliance.
-
Paid remaining $926,149 on Senior Note to Nirland Limited on Feb 13, 2025; all assets now free of liens.
-
Conduit Pharmaceuticals announces 1-for-100 reverse stock split to meet Nasdaq bid price requirement
Effective Jan 24, 2025 at 5pm ET; shares begin trading on split-adjusted basis Jan 27 under ticker CDT.
-
Nasdaq notifies Conduit of delisting due to low price; shareholders approve reverse stock split
Closing bid price ≤ $0.10 for 10 consecutive days; delisting set for Dec 27 unless hearing requested.
-
Issued $5,737,500 convertible note to A.G.P. for deferred commission; 5.5% interest, matures Nov 25, 2025.
-
Conduit Pharmaceuticals secures $1.2M in new loans; issues warrants and amends existing debt
Entered Bridge Loan with A.G.P. for up to $600k at 4.21% due Dec 31, 2024; issued warrants for 2.86M shares at $0.1048 per share, subject to shareholder approval.
-
Nasdaq notified Conduit on Aug 15, 2024 for non-compliance: MVPHS <$15M and MVLS <$50M; 180-day cure period until Feb 11, 2025.
-
Conduit licenses three AstraZeneca assets for autoimmune and infertility; issues 9.5M shares
Exclusive license from AstraZeneca for HK-4 glucokinase activators AZD1656, AZD5658 and MPO inhibitor AZD5904.
-
Conduit Pharmaceuticals issues $2.65M secured note at 12%, 12.5M shares to Nirland
Senior Secured Promissory Note of $2,650,000 (incl. $500,000 OID), 12% interest, matures Aug 5, 2025.
-
Conduit Pharma gets Nasdaq deficiency notice after audit committee director resigns
Nasdaq notified Conduit on May 28, 2024 that audit committee now has only two independent directors.
Executive changes
Appointed
Simon Fry
director
CDT ·
CDT Equity Inc.
the Board of Directors (the “Board”) of Conduit Pharmaceuticals Inc. (the “Company”) appointed Simon Fry as a director, and a member of the Audit Committee and the Compensation Committee, to become effective on December 18, 2024
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material